JAMA Network
About The Study: In patients with cryptogenic stroke and evidence of atrial cardiopathy without atrial fibrillation, oral anticoagulant therapy with apixaban did not significantly reduce recurrent stroke risk compared with aspirin in this randomized clinical trial that included 1,015 participants.
Authors: Hooman Kamel, M.D., of Weill Cornell Medicine in New York, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2023.27188)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
